madopar quick lausnartafla 100 mg/25 mg
roche pharmaceuticals a/s - levodopum inn; benserazidum hýdróklóríð - lausnartafla - 100 mg/25 mg
madopar quick lausnartafla 50 mg/12,5 mg
roche pharmaceuticals a/s - levodopum inn; benserazidum hýdróklóríð - lausnartafla - 50 mg/12,5 mg
nicorette quickmist munnholsúði, lausn 1 mg/skammt
mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt
nicorette quickmist cool berry munnholsúði, lausn 1 mg/skammt
mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. sjá kafla 4. 4 og 5.
nicorette (lyfjaver) munnholsúði, lausn 1 mg/skammt
lyfjaver ehf. - nicotinum - munnholsúði, lausn - 1 mg/skammt
nicorette (heilsa) munnholsúði, lausn 1 mg/skammt
heilsa ehf. - nicotinum - munnholsúði, lausn - 1 mg/skammt
nicorette invisi forðaplástur 10 mg/16 klst.
mcneil denmark aps - nicotinum - forðaplástur - 10 mg/16 klst.
nicorette invisi forðaplástur 15 mg/16 klst.
mcneil denmark aps - nicotinum - forðaplástur - 15 mg/16 klst.
nicorette invisi forðaplástur 25 mg/16 klst.
mcneil denmark aps - nicotinum - forðaplástur - 25 mg/16 klst.